Indicated for: dyslipidemia
Route of administration: oral
Substance: nicotinic acid + laropiprant (lipid-lowering agents)
ATC: C10AD52 (Cardiovascular system | Lipid modifying agents, plain | Nicotinic acid and derivatives)
The combination of nicotinic acid and laropiprant is used to treat dyslipidemia, particularly to lower LDL cholesterol and triglycerides and increase HDL cholesterol. Laropiprant helps reduce the flushing side effect caused by nicotinic acid.
This combination is indicated for patients at high risk of cardiovascular diseases, especially when other treatments are not tolerated or effective. It is available in oral tablet form.
Side effects may include nausea, stomach discomfort, itching, or dizziness. Skin flushing is significantly reduced due to the presence of laropiprant.
Patients should inform their doctor about any liver conditions or other health issues before use. Monitoring liver function is recommended during treatment.